ClinicalTrials.gg
RecruitingNCT05641259Updated Sep 11, 2026

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

A Phase 1 interventional study of LP-108 and Azacitidine in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, sponsored by Guangzhou Lupeng Pharmaceutical Company LTD.. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Guangzhou Lupeng Pharmaceutical Company LTD. (part of Lupeng Pharmaceutical Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
198
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
60th of 433
198 · median 50
Started
2023
with 53 others
Phase 1
121 of 473
69 open now
Primary completion
2027-12
later than 205 of 288 live
Registered
215th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 60th largest by planned enrollment of the 433 interventional ones that give a count, is one of 54 that started in 2023, is one of 121 in phase 1, reaches primary completion later than 205 of the 288 other live ones, and was the 215th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, multicenter, dose-escalation \& expansion study to evaluate the safety,tolerability and pharmacokinetics (PK) of LP-108, a BCL-2 inhibitor, combined with azacitidine, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RP2D), and to assess the preliminary efficacy of this combination.

Read the detailed description

This Phase 1 study will look at different doses and different treatment schedules in order to better understand the effects of the combined regimens on the newly diagnosed or refractory/relapsed adult participants with AML ,MDS or CMML. The procedures include screening for eligibility, study treatments, and blood \& bone marrow tests. All the safety events will be record, pharmacokinetic parameters (Tmax, Cmax,T1/2, AUC et al.) will be calculated, response and survival will be assess during the study. Participants will be treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must has a diagnosis of one of the following: (R/R) or untreated ineligible for treatment with a standard induction chemotherapy acute myeloid leukemia (AML) ; R/R myelodysplastic syndrome(MDS) or untreated MDS with excess blasts defined as ≥ 5% blasts in either bone marrow or blood or with high risk (high and very high-risk groups according to IPSS-R) ;CMML-1 or 2 by WHO, no requirements for prior therapy.
  • performance status ≤ 2.
  • Estimated survival ≥ 12 weeks.
  • Baseline white blood cell count (WBC) ≤ 25 x 109/L.
  • Subject must has adequate organ function as defined below: (AST) and alanine transaminase (ALT)≤3 x ; ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin); adequate renal function as demonstrated by a ≤1.5 x ULN ; calculated by the Cockcroft Gault formula; ≤ 1.5 x ULN, INR ≤ 1.5 x ULN.
  • Prior treatment-related toxicities must be grade 1 or baseline except for alopecia.
  • If subject is sexually active, he/she must agree to carry out throughout the study and 90 days after the last dose of LP-108. Subject must agree to have a negative serum β-HCG test result within 7 days prior to study drug.
  • Subject must voluntarily sign and date an .

Exclusion criteria

Exclusion Criteria:

  • Subject is allergic to LP-108, Azacitidine or , or with poor tolerance to Azacitidine.
  • Subject has received prior therapy with a BH3 mimetic.
  • Subject has acute promyelocytic leukemia.
  • Subject has t(9;22) karyotype abnormality or positive BCR/ABL1 fusion gene.
  • Subject has known and active CNS involvement.
  • Subject has myeloid sarcoma but no bone marrow involvement.
  • Subject has Acute unidentified leukemia.
  • Subject has treatment related MDS or AML.
  • Subject has AML/MDS/CMML with myelofibrosis ≥ grade 2.
  • Subject has received Hematopoietic Stem Cell Transplantation (HSCT) or autologous HSCT within 3 months prior to the first dose of study drug.
  • Subject must be at least 4 weeks from antitumor therapy, major surgery, radiation therapy, or participation in other trials.
  • Subject has received a strong and/or moderate inhibitor or inducer, P-gp inhibitor or CYP2C8 substrate within 14 days prior to the initiation of study treatment.
  • Subject has received drugs with a potential to cause prolonged or torsade de pointes.
  • Administration or consumption of any of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges (including marmalade containing Seville oranges); Star fruit.
  • Subject has known within 3 years prior to the first dose of study drug, with the exception of: Adequately treated basal skin cancers, in situ carcinoma of the cervix uteri or breast, localized squamous cell carcinoma.
  • Subject has serious and/or uncontrolled systemic diseases, in the opinion of the investigator, the subject is inappropriate for enrollment into this study (serious active infection with grade ≥ 2(based on ), high blood pressure that cannot be controlled by medication, diabetes, unstable angina, congestive heart failure, Respiratory diseases requiring continuous oxygen intake, severe vascular embolism, uncontrolled massive bleeding or bleeding from vital organs, severe liver, kidney or metabolic diseases, such as cirrhosis, kidney failure, etc.).
  • Subject has myocardial infarction or stroke within 6 months prior to the first dose of study drug.
  • Subject has a cardiac history including the following: History of CHF requiring treatment or \<50% or a cardiovascular disability status of .
  • Subject has uncontrolled and/or active systemic infection (viral, bacterial or fungal).
  • Subject has difficulty to swallow pills or has conditions that affect drug absorption or pharmacokinetics.
  • Strong and/or moderate CYP3A inhibitor or inducer and CYP2C8 substrate cannot be discontinued during the study.
  • Vaccination with live, attenuated vaccines ≤4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study or 4 weeks after the last dose of study drug.
  • Subject has an disease that requires therapy In the opinion of the investigator, the subject is inappropriate for enrollment into this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at escalating dose levels in participants with AML, MDS or CMML. Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0). Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons.

    Drug: LP-108 · Drug: Azacitidine

  • Experimental
    Safety Expansion

    LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: Participants with AML, MDS or CMML will be treated with LP-108 to enable selection of the recommended Phase 2 dose (RP2D). Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0). Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons.

    Drug: LP-108 · Drug: Azacitidine

  • Experimental
    Efficacy Expansion [AML]

    LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at RP2D level in participants with AML . Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0). After the completion of Part 1, the Part 2 dose expansion phase will begin. Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons.

  • Experimental
    Efficacy Expansion [MDS&CMML]

    LP-108: Cycle 0: ramp-up, Cycle 1+: at RP2D level in participants with MDS or CMML. Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0). Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons.

Interventions

  • DrugLP-108

    Oral administration for 21 or 28 days on a 28-day cycle

  • Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose(MTD)

    Standard phase I 3+3 design. The first 3 subjects will be assigned to dose level 1 cohort. If none of the first three subjects experiences DLT, escalation to dose level 2 cohort is permitted. If one of the first three subjects' experiences DLT, a total of six subjects will be required in that dose cohort, and escalation will only be permitted if five of six subjects do not experience DLT. If more than one DLT is observed in the dose level 2 cohort, this will be determined to be the maximally administered dose, and three more subjects will be enrolled in the dose level 1 cohort if only three were previously treated at that dose. Escalation from dose level 2 to level 3 cohort will be with the same method as before. The MTD will be the cohort in which ≤1/6 subjects have dose limiting toxicity at the dose prior to the maximally administered dose. If the dose level 3 cohort has ≤1/6 subjects with a DLT, the MTD will not have been reached.

    Time frame: Up to 42 days after initial dose of study drug at the designated cohort dose.

  2. Recommended Phase 2 Dose(RP2D)

    RP2D will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.

    Time frame: Up to 1.5 years

  3. Incidence of AEs

    Type, frequency and severity of AEs, relationship of AEs to study treatment

    Time frame: From first dose of study drug to 28 days after last dose of study drug

  4. Incidence of clinically significant changes in clinical laboratory results

    Clinically significant changes in hematology, chemistry, coagulation and urinalysis tests results.

    Time frame: From first dose of study drug to 28 days after last dose of study drug

  5. Cmax of LP-108

    Maximum plasma concentration (Cmax) of LP-108.

    Time frame: Up to 24 hours post dose

  6. Tmax of LP-108

    Time to maximum plasma concentration (Tmax) of LP-108.

    Time frame: Up to 24 hours post dose

  7. t1/2 of LP-108

    The terminal elimination half-life (t1/2).

    Time frame: Up to 24 hours post dose

  8. AUC0-t of LP-108

    Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration of LP-108.

    Time frame: Up to 24 hours post dose

  9. CL/F of LP-108

    Apparent clearance (CL/F) of LP-108.

    Time frame: Up to 24 hours post dose

  10. Vd/F of LP-108

    Apparent volume of distribution of LP-108.

    Time frame: Up to 24 hours post dose

Secondary outcomes

  1. Objective Response Rate (ORR)

    Response criteria follows the 2017 European Leukemia Net (ELN) recommendations for AML( CR, CRi, PR) , the International Working Group (IWG) response criteria for MDS(CR, PR, marrow CR, HI), the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults(CR, PR, Marrow response, Clinical benefit).

    Time frame: Measured from Cycle 1 Day 1 to 28 days after last dose of study drug, and assessed up to 24 months.

  2. Progression-Free Survival(PFS) (only for MDS or CMML)

    PFS is defined as the number of days from the date of the first dose of study drug to the date of earliest disease progression or death.

    Time frame: Measured from the date of first dose of study drug to the date of earliest disease progression or death or last visit, and assessed up to 24 months.

  3. Time to Response(TTR)

    TTR is defined as the number of days from the date of the first dose of study drug to the date of earliest response.

    Time frame: Measured from the date of the first dose of study drug to the date of earliest response, and assessed up to 6 months.

  4. Duration of Response(DOR)

    DOR is defined as the number of days from the date of the first remission to the date of earliest disease progression or death.

    Time frame: Measured from the date of the first remission to the date of earliest disease progression or death, and assessed up to 24 months.

  5. DOCR (only for CR/CRi participants)

    DOCR is defined as the number of days from the date of the first CR/CRi to the date of earliest disease progression or death.

    Time frame: Measured from the date of the first CR/CRi to the date of earliest disease progression or death, and assessed up to 24 months.

  6. Event-free Survival (EFS)

    EFS is defined as the number of days from the date of first dose to the date of earliest evidence of disease progression/relapse, or initiation of new non-protocol-specified antitumor therapy without documented progression, or death.

    Time frame: Measured from the date of first dose to the date of earliest evidence of disease progression, initiation of new non-protocol-specified antitumor therapy without documented progression, death, and for up to 5 years after the last subject is enrolled.

  7. OS

    OS is defined as the number of days from the date of first dose to the date of death.

    Time frame: Measured from the date of date of first dose to the date of death or last visit, and for up to 5 years after the last subject is enrolled.

07

Study locations

3 of 3 sites recruiting
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting
    • Fei Li · Contact
  • First Affiliated Hospital of Soochow University
    Suzhou, China
    Recruiting
    • Depei Wu · Contact
  • Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital
    Zhengzhou, China
    Recruiting
    • Fei Li · Contact
08

References and documents

Publications

  • Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. PubMed 27895058 ↗
  • Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25. doi: 10.1182/blood-2005-10-4149. Epub 2006 Apr 11. PubMed 16609072 ↗
  • Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MDS/MPN International Working Group. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26. PubMed 25624319 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 58 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2022
First posted
Dec 7, 2022
StartActual
Feb 14, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05641259
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Feb 14, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Yue Shen, PhD
Contact
yshen@lupengbio.com
86-020-31605119
Depei Wu, PhD
study chair · First Affiliated Hospital of Soochow University
Xudong Wei, PhD
principal investigator · Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital
Qiubai Li, PhD
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Li Wang, PhD
principal investigator · First Affiliated Hospital of Chongqing Medical University
Fei Li, PhD
principal investigator · The First Affiliated Hospital of Nanchang University
Xiaojing Yan, PhD
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lacutoclax

Start the discussion